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Human placental uptake 
of glutamine and glutamate 
is reduced in fetal growth 
restriction
Kirsty R. Mcintyre1,2,3*, Kirsty M. M. Vincent1,2, Christina E. Hayward1,2, Xiaojia Li1,2, 
colin p. Sibley1,2, Michelle Desforges1,2, Susan L. Greenwood1,2 & Mark R. Dilworth1,2
Fetal growth restriction (FGR) is a significant risk factor for stillbirth, neonatal complications and 
adulthood morbidity. Compared with those of appropriate weight for gestational age (AGA), FGR 
babies have smaller placentas with reduced activity of amino acid transporter systems A and L, 
thought to contribute to poor fetal growth. the amino acids glutamine and glutamate are essential 
for normal placental function and fetal development; whether transport of these is altered in FGR is 
unknown. We hypothesised that FGR is associated with reduced placental glutamine and glutamate 
transporter activity and expression, and propose the mammalian target of rapamycin (mTOR) 
signaling pathway as a candidate mechanism. FGR infants [individualised birth weight ratio (IBR) < 5th 
centile] had lighter placentas, reduced initial rate uptake of 14c-glutamine and 14c-glutamate (per 
mg placental protein) but higher expression of key transporter proteins (glutamine: LAT1, LAT2, 
SNAT5, glutamate: EAAT1) versus AGA [IBR 20th–80th]. In further experiments, in vitro exposure to 
rapamycin inhibited placental glutamine and glutamate uptake (24 h, uncomplicated pregnancies) 
indicating a role of mtoR in regulating placental transport of these amino acids. these data support 
our hypothesis and suggest that abnormal glutamine and glutamate transporter activity is part of the 
spectrum of placental dysfunction in FGR.
Fetal growth restriction (FGR), which affects approximately 5% of pregnancies, refers to the inability of a fetus 
to achieve its growth potential and is primarily caused by placental  dysfunction1. FGR is a major risk factor for 
stillbirth and neonatal, childhood and adulthood  morbidity2–5. Despite the significant societal and economic 
burden of  FGR6–8 there are currently no approved pharmacological treatments  available9. The reticence to develop 
novel therapies for placental dysfunction in part reflects concerns of potential fetal toxicity but is also influenced 
by an incomplete understanding of placental function in health and  disease10. FGR is often associated with one, 
or a combination of, the following characteristics: small placental size, abnormal placental structure, abnormal 
uteroplacental and fetoplacental blood flow, and abnormal function of the syncytiotrophoblast, the transporting 
epithelium of the  placenta1,11–15. Inconsistencies in the definition of FGR prompted a recent Delphi study, which 
recommended a consensus-based clinical definition of  FGR16.
In women, FGR is associated with reduced placental activity (per mg membrane protein) of a number of 
amino acid transporter systems including systems A and  L13–15,17. Furthermore, in a rat model of FGR, reduced 
placental amino acid transport by system A is evident prior to the reduction in fetal  growth18, whilst inhibition of 
placental system A directly results in reduced fetal  growth19, demonstrating that a reduction of placental amino 
acid provision by system A can cause FGR.
The amino acids glutamine and glutamate are essential for pH homeostasis, nucleotide synthesis and protein 
 anabolism20,21. Glutamine is a non-essential amino acid that becomes conditionally essential during pregnancy 
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as fetal demand exceeds maternal  synthesis22,23. Demand is met through interorgan recycling of glutamine and 
glutamate. Deamination of glutamine in the fetal liver produces glutamate, an important nitrogen resource and 
precursor of γ-amino butyric acid (GABA), a key inhibitory  neurotransmitter23–25. Glutamate is transported 
across the syncytiotrophoblast microvillous membrane (MVM: maternal facing) and basal membrane (BM: 
fetal facing) by high affinity Excitatory Amino Acid Transporters (EAATs; system  XAG-)26 and is converted to 
glutamine in the  placenta27. Glutamine is a substrate of the amino acid transporter systems A (isoforms SNAT1, 
2 and 4), N (SNAT5), L (LAT1 and 2),  y+L and  ASC21. However, system  y+L-mediated glutamine transfer across 
the MVM is negligible and system ASC isoforms are predominantly localised to the  BM28.
There are as yet no studies of placental glutamine and glutamate transport in the placenta in human FGR 
but, as noted above, substantial evidence to show that system A and system L transporter activity is reduced 
in this  condition13–15,17. The reasons behind the reduction in placental system A and system L activity in FGR 
are poorly understood, not least because the determinants of appropriate provision of amino acids to the fetus 
in normal pregnancy have not been adequately defined. However, there is evidence that the mammalian target 
of rapamycin (mTOR) signaling pathway, specifically mTOR complex 1 (mTORC1), regulates system A and L 
activity through reduced plasma membrane trafficking of SNAT2 in the case of system  A29,30 and that placental 
mTOR activity, as evidenced by reduction in the important downstream signaling molecule phosphorylated 
ribosomal S6 kinase (phospho-S6K1), is reduced in  FGR29,31. The mTOR pathway, proposed to act as a nutrient 
sensor, is thus a candidate mechanism by which glutamine and glutamate transport is modulated in normal 
pregnancy, though this has never been tested.
In the current investigation we tested the hypotheses that (a) placental glutamine and glutamate transporter 
expression and activity is reduced in FGR infants compared with infants appropriately grown for gestational 
age (AGA), and (b) inhibiting mTOR activity in placentas from uncomplicated pregnancies would result in a 
reduction in placental uptake of glutamine and glutamate.
Results
transporter-mediated uptake of 14C‑glutamine, 14c-glutamate and 14C‑MeAIB is reduced in 
FGR pregnancies. A summary of the demographics of study participants is shown in Table 1. FGR infants 
weighed significantly less than AGA infants (P < 0.001) and had significantly lighter placentas (P < 0.001). There 
was a difference in the gestational age of FGR babies compared with AGA babies (Table 1; P < 0.05). Transporter-
mediated uptake of 14C-glutamine, 14C-glutamate (validation of method: Supplementary Fig. 1) and 14C-MeAIB 
at initial rate was significantly lower in placentas of FGR babies (IBR < 5th centile) compared with placentas 
of AGA babies (IBR 20th–80th centile, P < 0.05) (Fig. 1). There was no effect of gestational age on amino acid 
uptake (Supplementary Fig. 2).  
Linear regression analyses fitted to all data indicated that transporter-mediated uptake of 14C-glutamine 
at 90 min was correlated with uptake of 14C-MeAIB (P < 0.05) and 14C-glutamate (P < 0.001, Supplementary 
Fig. 3). However, when analyses were fitted to either AGA or FGR groups, we found that the correlation between 
14C-glutamine and 14C-MeAIB only remained for placentas from FGR babies (P < 0.05), highlighting the impor-
tance of system A in these pregnancies. 14C-glutamine and 14C-glutamate uptake was correlated for both AGA 
and FGR infants, which suggests that there is an intrinsic relationship between the uptake of these two amino 
acids that is not altered in FGR.
Total amino acid availability for transfer from the placenta to the fetus is reduced in FGR versus 
AGA infants. Trimmed placental weight and birth weight were correlated for both AGA (P < 0.05) and FGR 
Table 1.  Maternal and fetal demographics from AGA and FGR cohorts. Data are median (range) or 
percentage of total. Analysis by Mann–Whitney test or by Fishers exact test (mode of delivery, ethnicity and 
smoking status). ELCS elective caesarean section, EMCS emergency caesarean section, NVD normal vaginal 
delivery.
AGA (n = 14) FGR (n = 11) P value
Maternal age (years) 34 (23–40) 32 (25–39) 0.946
Body mass index (kg/m2) 24.9 (18.8–31.2) 23.9 (19.8–33.9) 0.442
Birth weight (g) 3355 (2820–3960) 1730 (717–2860)  < 0.001
Trimmed placental weight (g) 498.1 (402.3–719.4) 301.6 (159.5–429.3)  < 0.001
Individualised birth weight ratio (IBR) 53.6 (26.4–79.2) 1 (0–3.5)  < 0.001
Gestation (weeks + days) 39 + 0 (37 + 1–40 + 2) 35.2 (29 + 1–40 + 4) 0.049
Mode of delivery ELCS (89%) ELCS (55%)
0.623NVD (11%) EMCS (18%)
NVD (27%)
Parity 1 (0–8) 1 (0–5) 0.315
Gravidity 2 (1–12) 2 (1–6) 0.971
Ethnicity Caucasian (71%) Caucasian (64%) 0.999
Smoking status (yes/no) No (100%) No (73%) 0.072
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Figure 1.  Transporter-mediated uptake of 14C-glutamine (a), 14C-glutamate (b) and 14C-MeAIB (c) by placental 
villous fragments from AGA infants (n = 13–14, solid symbols) and FGR (n = 10–11, hollow symbols). Data 
are mean ± SEM * P < 0.05 Linear regression analysis showed a significant difference in elevation for glutamine 
(P < 0.02), glutamate (P < 0.02) and MeAIB (P < 0.03) uptake in FGR versus AGA.
Figure 2.  Correlation between trimmed placental weight and birth weight (a) for AGA (n = 14, solid 
symbols) and FGR infants (n = 11, hollow symbols) ** P < 0.01, * P < 0.05: Linear regression. Availability of 
14C-glutamine (b), 14C-glutamate (c) and 14C-MeAIB (d) for delivery to the fetus in placentas from AGA 
compared with FGR infants. *** P < 0.001, ** P < 0.01: Mann–Whitney test.
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Figure 3.  Expression of glutamine [LAT1 (a), LAT2 (b), SNAT5 (c)] and glutamate [EAAT1 (d), EAAT2 (e)] 
transporter proteins in membrane-enriched placental homogenates from AGA (n = 7–11) and FGR (n = 8–10) 
infants. Densitometric analysis is expressed as a ratio of β-tubulin signal. Line denotes median, *** P < 0.001, * 
P < 0.05: Wilcoxon signed-rank test.
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(P < 0.01) infants (Fig. 2A). A proxy measure of the availability of amino acids (14C-glutamine, 14C-glutamate 
and 14C-MeAIB) for transfer from the syncytiotrophoblast to the fetus [trimmed placental weight (g) × amino 
acid uptake at 90 min (per mg placental villous fragment protein)] was significantly lower for placentas of FGR 
versus AGA infants (Fig. 2B–D).
Placental transporter protein and mRNA expression is altered in FGR versus AGA 
infants. Expression of glutamine transporter proteins (system L: LAT1, 2, and system N: SNAT5) was sig-
nificantly higher in placentas from FGR (IBR 0.0–3.5) versus AGA (IBR 27.9–79.1) pregnancies (Fig. 3A–C, 
P < 0.05). Expression of EAAT1 (glutamate is a substrate) was significantly higher in placentas from FGR versus 
AGA infants (Fig. 3D, P < 0.001). EAAT2 expression was not different between groups (Fig. 3E). Expression of 
β-tubulin was not different between AGA and FGR groups. Full-length blots are presented in Supplementary 
Fig. 4.
It was not possible to assess protein expression of system A transporter isoforms (SNAT1, 2 and 4), as there 
were no suitably validated commercially available antibodies. However, expression of the gene that encodes the 
system A isoform SNAT2 (SLC38A2) was significantly higher in placentas from FGR than AGA babies (P < 0.01) 
(Fig. 4B). Conversely, SLC38A4 mRNA expression (encodes SNAT4) was significantly lower in placentas from 
FGR versus AGA pregnancies (P < 0.01) (Fig. 4C); expression of SLC38A1 (encodes SNAT1) was not significantly 
different between placentas of AGA and FGR infants (Fig. 4A).
Rapamycin inhibits steady state accumulation of 14C‑MeAIB, 14c-glutamine and 14c-gluta-
mate by placental fragments from uncomplicated pregnancies. Rapamycin caused a concentra-
tion-dependent inhibition of 14C-MeAIB, 14C-glutamine and 14C-glutamate uptake by placental villous explants 
from uncomplicated pregnancies (IBR 20–70) over 24 h, which was significantly lower than control at 150 nM 
(Fig. 5; 14C-MeAIB P < 0.001; 14C-glutamate P < 0.01; 14C-glutamine P < 0.05 versus control). Uptake of the radi-
olabelled amino acids was reduced to 15–30% (range) of control by the  Na+/K+-ATPase inhibitor ouabain, indi-
cating that at least 70% of radiolabel accumulation by the tissue over 24 h could be attributed to amino acid 
transporter activity, driven by an inwardly directed  Na+ gradient. Neither rapamycin nor ouabain altered the 
uptake of 14C-3-0-methylglucose (3-0MG) over 24 h (Supplementary Fig. 5). The transporter-mediated uptake 
of 14C-MeAIB, 14C-glutamine and 14C-glutamate was also reduced by a high concentration (10 mM) of unla-
belled MeAIB, glutamine and glutamate to 35%, 28% and 13% of control respectively (Fig. 5).
Phospho‑S6K1 but not total S6K1 expression is inhibited by rapamycin. Both time and exposure 
to rapamycin had an overall effect in reducing placental (uncomplicated pregnancies; IBR 37.1–96.6) expression 
of phosphorylated ribosomal S6 kinase (phospho-S6K1, Fig. 6A,C). When comparing groups directly at each 
Figure 4.  mRNA expression of SLC38A1 (a), SLC38A2 (b) and SLC38A4 (c) in placentas from AGA (n = 8–11) 
and FGR (n = 8–9) placentas, normalised to the geometric mean of YWHAZ and TBP. ** P < 0.01: Mann–
Whitney test.
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timepoint, expression of phospho-S6K1 was lower in the rapamycin versus control groups at 1 and 2 h (P < 0.05) 
with a trend towards significance at 4 h (P = 0.07, Fig. 6C). Rapamycin had no effect on total S6K1 expression at 
any timepoint (Fig. 6B,D). Full-length blots are presented in Supplementary Fig. 6.
Figure 5.  Effect of rapamycin on 14C-MeAIB (a) 14C-glutamine (b) and 14C-glutamate (c) uptake into placental 
villous explants (n = 6) over 24 h. *** P < 0.001, ** P < 0.01, * P < 0.05 versus control: ANOVA with Dunn’s multi-
comparison post hoc test. 1 mM ouabain (inhibitor of  Na+/K+-ATPase) reduced uptake of all radiolabelled 
amino acids by 70–85% (* P < 0.03: Wilcoxon matched pairs; n = 6 placentas). 10 mM unlabelled amino acids 
[MeAIB (a) Gln = glutamine (b) Glt = glutamate (c); competing substrate] significantly reduced uptake of the 
corresponding radiolabelled amino acid (* P < 0.02: Mann–Whitney; n = 3 placentas). Line denotes median.
Figure 6.  Representative western blots of phospho-S6K1 (a) and total S6K1 (b) protein in placental villous 
explants treated for 1, 2, 4 and 24 h with (R) or without (control, C) 150 nM rapamycin. Densitometric analysis 
is expressed as a ratio of β-actin signal. Data are shown in (C) and (D) (n = 5 placentas). Line denotes median, * 
P < 0.05: 2-way repeated measures ANOVA with Sidak test.
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Discussion
In agreement with our hypothesis this study shows that initial rate uptake of glutamine and glutamate, important 
amino acids for fetal growth and placental metabolism, into placental villous fragments is reduced in FGR. This 
reduction was not accompanied by reduced expression of transporters utilised by glutamine and glutamate. To 
the contrary, expression of the transporter proteins, LAT1, LAT2, SNAT5 and EAAT1 were increased in placental 
homogenates of FGR versus AGA infants. Reasons for this disparity are not known at present but possibilities 
are discussed below.
In both AGA and FGR, we estimate that approximately twice as much glutamate as glutamine is transported 
across the MVM (taking into account that different concentrations of these radiolabeled amino acids were used 
for the initial rate uptake experiments: see Methods). This is probably reflective of the fact that glutamate is 
readily metabolised to glutamine in the cytosol of the syncytiotrophoblast for subsequent transfer to the fetus 
and reinforces the importance of glutamate, albeit indirectly, for fetal growth as previously suggested in  mice32. 
Worthy of note is that measures of 14C uptake in these studies are unable to discriminate between glutamine 
and glutamate should interconversion have taken place. If interconversion did occur over the time course of the 
experiment (30–90 min), the studies show that there is a reduction in 14C labelled substrates, important for both 
placental metabolism and fetal growth, in FGR versus AGA.
In the current study we have also shown that, in uncomplicated pregnancies, exposure to rapamycin inhibits 
placental glutamine and glutamate uptake at steady state. The involvement of mTOR in this effect is evidenced 
by the reduction in phospho-, but not total, S6K1 expression following rapamycin exposure. Experiments were 
performed to assess the contribution of transporter-mediated glutamine and glutamate uptake to the total accu-
mulation over 24 h. Using a high concentration of unlabelled substrates to compete for binding sites on the 
transporters, or ouabain to reduce the activity of transporters primarily- and secondarily-dependent on the 
intracellular  Na+ gradient (latter include exchangers such as system L, which rely on intracellular substrates that 
are taken up by  Na+ dependent transporters), we showed that a maximum of 30% of amino acid uptake over 24 h 
could be by non-specific diffusion (e.g. through the lipid bilayer or damaged areas of tissue). Accordingly, it is 
likely that rapamycin reduced MeAIB, glutamine and glutamate uptake by inhibiting the activity of the trans-
porter systems A, L and  XAG-. This effect is consistent with our hypothesis and with the regulation of system A 
and L transporter activity by mTOR reported  previously30.
Our data are consistent with existing reports in the literature that FGR fetuses have smaller placentas than 
AGA  babies1 and demonstrate reduced transporter-mediated uptake of 14C-MeAIB (system A activity)13–15,33. 
Placental uptake of amino acids is important for their subsequent delivery to the fetus and also for modifying the 
intracellular pool of amino acids available for exchange, for example by system L  transporters34. One may expect 
a smaller placenta (by weight) to have less surface area available for exchange. Indeed in FGR, the surface area 
of terminal villi and capillaries is  decreased35. Ideally, surface area available for nutrient transport would be used 
as the denominator by which to calculate amino acid transporter activity. However, in the absence of a method 
to accurately measure syncytiotrophoblast MVM surface area for this assay, placental uptake was measured 
per mg protein as a proxy measure of placental size. Reduced amino acid uptake (per mg placental protein) in 
combination with a smaller placenta theoretically contributes to reduced amino acid availability for delivery 
to the fetus, as illustrated by the proxy measure of total amino acid within the syncytiotrophoblast available for 
exchange (Fig. 2B–D). It is also postulated that a reduction in initial rate uptake of glutamine and glutamate will 
lead to a lower intracellular concentration in placentas of FGR compared with AGA  pregnancies36. Reductions 
in amino acid availability thus offer a rationale as to why fetal growth may be compromised in FGR. Further 
work is required to establish the impact of reduced amino acid uptake in FGR on the composition of amino acid 
pools within the placenta.
A limitation of the study was the significant difference in the gestation of FGR samples compared with AGA 
(Table 1). However, analyses performed confirmed no difference in uptake of radiolabeled amino acids from 
preterm compared to term delivery (Supplementary Fig. 2).
Transporter abundance was assessed as a potential mechanistic explanation for the reduction in amino acid 
transporter activity in FGR. However, the data presented here show a disparity between transporter activity and 
expression. In FGR, placental expression of LAT1, LAT2, SNAT5 and EAAT1 transporter proteins was higher 
compared with AGA. This is in agreement with previous reports that LAT1 expression, as analysed by immuno-
histochemistry, is increased in the MVM of the syncytiotrophoblast in  FGR37. This is the first study to show that 
placental system N and  XAG- (SNAT5 and EAAT1) protein expression is also elevated in FGR.
Assessment of system A transporter proteins by Western blotting was not conducted in the current study due 
to an absence of commercially available and validated antibodies that reliably produce a specific signal. Instead, 
we evaluated mRNA expression and found that placental SLC38A2 (SNAT2) expression was higher and SLC38A4 
(SNAT4) expression lower in FGR compared with AGA pregnancy. These data conflict with previous observa-
tions from a similar study cohort in  humans31 (FGR < 3rd centile versus AGA 25th–75th centile, non-customised 
growth charts) that reported reduced SNAT1 and 2, and no difference in SNAT4, protein expression in MVM 
isolates from FGR compared with AGA infants; no differences were found when whole homogenates was com-
pared. Furthermore, a study by Malina et al., compared SLC38A1 and SLC38A2 mRNA expression between 
placentas of women with SGA (< 10th centile) and normal birth weight infants and demonstrated no difference 
between  groups38. Experiments in animal models yield conflicting results. Placental SNAT1 and 2 expression is 
reduced in the MVM of a protein restricted rat model of FGR but not in a protein-restricted baboon  model39,40. 
In the placental-specific Igf2 knockout mouse, a well characterized model of FGR, placental expression of Slc38a4 
is elevated compared with wild-type mice earlier in pregnancy (embryonic day 16) but normalizes near term 
whilst expression of Slc38a1 and Slc38a2 are no different at either gestational time  point41. The mechanisms 
that underpin these disparate observations remain unclear but likely relate to species differences and also the 
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different perturbations to induce FGR in the animal models. In the current study, SLC38A1, 2 and 4 expression 
was measured following RNA extraction from villous tissue whereas previous studies determined SNAT1, 2 and 
4 protein expression in MVM isolates from human  placenta31.This might underlie the different findings between 
studies. The reduced expression of SLC38A4 in the current study could lead to a reduction in SNAT4 expression 
but it is unlikely that lower SNAT4 expression exclusively accounts for reduced glutamine uptake in FGR given 
that it is not considered to be substrate of this  isoform42.
The reduction in glutamine and glutamate uptake at initial rate in FGR (Fig. 1) but increase in transporter 
protein expression (measured in membrane-enriched placental isolates: Fig. 3) could be explained by a reduction 
in the insertion of the transport proteins into the MVM. Previously, reduced placental system A and L activity in 
FGR has been attributed to alterations in trafficking of amino acid transporters to the  MVM43 as a consequence 
of a reduction in activity of the mTORC1 signaling pathway. Inhibition of mTORC1 in cytotrophoblast cells 
activates the ubiquitin ligase Nedd4-231, which increases ubiquitination of specific isoforms of the system A and 
L transporters causing their removal from the plasma membrane, and a reduction in system A and L activity. 
This occurs without changing the overall cellular expression of these amino acid transporters. In FGR the activ-
ity of mTORC1 is reduced, and Nedd4-2 increased, compared with uncomplicated  pregnancy31, which raises 
the possibility that the reduction in activity of the glutamine and glutamate transporters observed in FGR in the 
current study could be due to ubiquitination of the transporters and their removal from the MVM. It is possible 
that the raised transporter protein expression in FGR is an adaptive response in an attempt to facilitate appro-
priate nutrient delivery to the fetus, but these proteins fail to be inserted into the MVM. To test this hypothesis 
it is essential that an assessment of protein expression in MVM, rather than the mixed membrane population 
employed here, be conducted. The reduced glutamine and glutamate uptake following inhibition of mTORC1 
by rapamycin observed in the current study shows that the activity of their respective transporters is regulated 
by mTORC1 in placental villous tissue of normal pregnancy. Further experiments are necessary to determine 
whether the reduction in glutamine and glutamate uptake in FGR is a consequence of reduced mTORC1 and 
increased Nedd4-2 activity lowering transporter expression in the MVM.
In conclusion, this study shows that the placental uptake of glutamine and glutamate is reduced in FGR, 
which may have consequences in terms of modulation of the placental amino acid pool and overall availability 
for transfer to the fetus. Deprivation of intracellular amino acids also compromises key aspects of syncytio-
trophoblast biology such as mitochondrial function and cell  renewal44. We also show that system  XAG-, which 
transports glutamate, is regulated by mTOR in normal pregnancy.
These studies contribute to our understanding of how amino acid transport into the placenta is regulated 
in normal pregnancy, and also add to the wealth of evidence for compromised placental amino acid transport 
in FGR. Improving placental amino acid transport could be a potential therapy for FGR but further studies 
are required to fully understand regulatory mechanisms of the different transporters and identify appropriate 
therapeutic targets.
Methods
tissue collection. Women who met the inclusion criteria (maternal age > 18 < 40 years; body mass index 
(BMI) > 19 < 30 kg/m2 at first antenatal appointment) were approached to take part in the study. However, dif-
ficulties obtaining tissue during the study from women with a BMI < 30 kg/m2 meant that some over this cut-off 
were included (n = 1 AGA: BMI 31.2, n = 1 FGR: BMI 33.9). Exclusion criteria were multiple pregnancy, con-
genital abnormalities or pre-gestational (e.g. hypertension) or gestational maternal disease (e.g. pre-eclampsia, 
gestational diabetes mellitus). IBR was calculated using GROW software (www.gesta tion.net). For the purpose 
of this study we defined FGR as an individualised birth weight ratio (IBR) < 5th centile, in alignment with the 
widely accepted threshold when this study began. AGA was classified as the 20th–80th centile to reduce the 
likelihood of including infants that are small or large for gestational age in the study population.
The placenta was collected immediately following delivery and trimmed placental weight (umbilical cord 
and placental membranes removed) recorded. Villous tissue was sampled according to a systematic sampling 
protocol and either used immediately for experiments requiring fresh tissue or stored at − 80 °C.
Freshly isolated villous tissue was used to compare initial rate 14C-glutamine and 14C-glutamate uptake in 
AGA and FGR. The benefit of this technique, compared with MVM vesicles, is the ability to assess amino acid 
uptake without compromising tissue integrity, intracellular signaling mechanisms and associated driving forces. 
The uptake of 14C-methylaminoisobutyric acid (MeAIB) was measured alongside as a positive experimental 
control. MeAIB is a non-metabolisable substrate of system  A45 and has been used extensively to assess placental 
system A activity in human and animal  studies15,46,47. Furthermore it is well established that placental system A 
activity is reduced in FGR versus AGA 13–15.
Development of a protocol to assess transporter‑mediated uptake of 14c-glutamine and 
14c-glutamate. A method is well established to assess system A activity in the MVM by determining 
 Na+-dependent uptake of 14C-MeAIB into villous fragments at initial  rate45,48. However, transporter-mediated 
14C-glutamine and 14C-glutamate uptake into villous fragments has not been reported previously and a pilot 
experiment was performed to determine (a) the optimal concentration of radioisotope (b) a strategy to detect 
the transporter-mediated component of 14C-glutamine and 14C-glutamate uptake, and (c) the time over which 
glutamine and glutamate transporter activity could be measured at initial rate.
Glutamine transport by syncytiotrophoblast MVM vesicles is mediated by  Na+-dependent systems A and 
N, and the  Na+-independent system  L28. 14C-glutamine uptake is inhibited by 5 mM histidine (substrate of 
system N) serine (substrate of system A) and 2-amino-2-norbornanecarboxylic acid (BCH, non-metabolisable 
analogue, substrate of system L)49. Therefore, the contribution of systems A, N and L to glutamine transport in 
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villous fragments was measured in Tyrode’s buffer in the absence of competitive substrates (total 14C-glutamine 
uptake comprising non-specific diffusion and transporter-mediated uptake) and in control (i.e.  Na+-containing) 
or  Na+-free Tyrode’s buffer [Tyrode’s buffer as described  previously50 with equimolar choline chloride to replace 
135 mM NaCl (pH 7.4 with KOH)] with 5 mM histidine, 5 mM serine and 5 mM BCH. For 14C-glutamate, 5 mM 
aspartic acid, a substrate of the  Na+-dependent system  XAG-28 was used, as described above.
Following tissue collection (described above), villous tissue was maintained in glutamine-free DMEM (1 g/
litre glucose, Life Technologies Ltd, Leicestershire, UK) supplemented with 864 μM glutamine and 120 μM 
glutamic acid mixed 1:1 with Tyrode’s  buffer50, for a final concentration of 432 μM and 60 μM, respectively, to 
mimic the concentration in maternal plasma before beginning the experimental protocol.
To measure uptake, placental villous tissue was exposed to 14C-glutamine (0.066 µCi/ml; 0.24 nmol/ml) and 
14C-glutamate (0.13 µCi/ml; 0.5 nmol/ml) for 10–120 min. After the elapsed time period, fragments were vigor-
ously washed for 2 × 15 s in 12 ml ice-cold Tyrode’s buffer (control or  Na+-free) then suspended in 4 ml water 
for 18 h. Lysed tissue fragments were incubated in 0.3 M NaOH (37 °C; overnight) and protein determined on 
the lysate by the Bio-Rad method. Initial rate uptake was expressed per mg fragment protein, using the latter as 
a proxy measure of fragment size. The transporter-mediated component was determined by subtracting uptake 
in  Na+-free Tyrode’s buffer containing competitive substrates from uptake under control conditions (Supple-
mentary Fig. 1).
Analysis by linear regression demonstrated that transporter activity was at initial rate over 30–90 min. Thus, 
definitive experiments measured 14C-glutamine, 14C-glutamate and 14C-MeAIB uptake over 30–90 min (n = 14 
AGA, 11 FGR) as described above and  previously45.
To test the hypothesis that diminished amino acid uptake may lead to decreased amino acid availability for 
transfer to the fetus, a proxy measure of amino acid availability was calculated as amino acid uptake at 90 min 
(per mg placental protein) × trimmed placental weight (g).
Effect of rapamycin on amino acid uptake at steady state. Placental villous fragments from 
uncomplicated pregnancies were dissected and processed under sterile conditions. Fragments were maintained 
in medium (DMEM 1880028: Gibco) supplemented with alanine (341 µM), glutamine (418 µM), glutamic acid 
(69 µM) and taurine (44 µM), streptomycin sulphate (100 mg/L), penicillin (60 mg/L) and gentamicin (1 ml/L) 
on Netwell permeable supports (Corning: 74 µM mesh; in a humidified incubator (37 ºC; 95 % air/5 %  CO2)). To 
measure amino acid uptake at steady  state36, fragments were incubated for 24 h with: 0.5 µCi/ml (8.5 nmol/ml) 
14C-MeAIB; 0.066 µCi/ml (0.24 nmol/ml) 14C-glutamine; 0.13 µCi/ml (0.5 nmol/ml) 14C-glutamate; or 0.5 µCi/
ml (8.5 nmol/ml) 14C-3-0-methylglucose (3-0MG). 3-0MG is a non-metabolised substrate of the GLUT trans-
porters and uptake of 3-0MG was measured to assess whether rapamycin had nonspecific effects on transporters 
and/or an effect on placental villus tissue integrity.
After 24 h, fragments were washed (2 × 15 s with 25 ml ice cold 0.9% saline) then lysed in 6 ml 0.3 M NaOH 
at 37 °C overnight to release the accumulated isotope. The radioactivity of the tissue lysate and culture medium 
was determined as described  previously45.
Rapamycin (Tocris, 53123-88-9) (n = 6 placentas) was added to the culture medium containing isotopes at 
20–150 nM for 24 h. The effect of rapamycin on 3-0MG uptake was measured to determine whether inhibition of 
mTOR would affect a non-amino acid facilitated diffusion transporter. Stock rapamycin was prepared in DMSO 
and diluted in culture medium; equivalent DMSO (0.1%) was added to control medium.
Two approaches were adopted to determine the contribution of transporter-mediated uptake versus non-
specific diffusion to the total uptake of radiolabelled amino acids at 24 h. Fragments were treated with 1 mM 
ouabain to block  Na+/K+-ATPase activity, raise intracellular  Na+  concentration51 and inhibit the activity of 
 Na+-dependent amino acid transporters (systems A, N and  XAG-). Additionally, fragments (n = 3 placentas) were 
incubated with a high concentration (10 mM) of unlabelled MeAIB, glutamine or glutamate to block uptake of 
the corresponding radiolabelled amino acids by competitive inhibition of the respective transporter proteins. 
Uptake in the presence of ouabain, or competing amino acids, is an estimate of non-specific diffusion.
placental protein expression of glutamine and glutamate transporters. Frozen placental tissue 
(n = 11 AGA, 10 FGR) was homogenised and centrifuged as previously  described52. Membrane-enriched frac-
tions were stored at − 80 °C for later Western blot analysis to detect LAT1, LAT2, SNAT5, EAAT1 and EAAT2. 
Proteins were separated by SDS-PAGE and transferred to Immobilon-FL PVDF membranes (Millipore UK 
Ltd., Watford, UK). Primary antibodies were: LAT1 (0.5 µg/ml; KE026; TransGenic Inc, Japan); LAT2 (2 µg/
ml; ab75610; Abcam, Cambridge, UK); SNAT5 (1.4 µg/ml; ab72717; Abcam), EAAT1 (1 µg/ml; ab416; Abcam) 
and EAAT2 (2.69 µg/ml; ab178401; Abcam). β-tubulin (2 µg/ml; ab6046; Abcam) was used as a loading control. 
Bands detected at the predicted molecular weight (kDa) were validated by the inclusion of positive controls 
(MVM) during antibody optimisation. Negative controls were by omission of primary antibody. Immunoreac-
tive species were detected with fluorescent-conjugated secondary antibodies (Li-COR Biosciences, Cambridge, 
UK) and membranes imaged using an Odyssey Sa Infrared Imaging System (Li-COR). Signal density was meas-
ured using Image Studio Lite (Li-COR). All signals were in the linear range of detection.
Placental protein expression of phospho‑S6K1 and S6K1 following rapamycin exposure. Pla-
cental villous explants were set up as described in the steady state measures section (n = 5). At 1, 2, 4 or 24 h, 
explants were taken and homogenised in RIPA lysis buffer (Sigma-Aldrich, UK, R0278) containing 10% PIC 
(Sigma-Aldrich, UK P8340) and 10% phosphatase inhibitor cocktails 2 and 3 (Sigma-Aldrich, UK, P5726 and 
P0044) using the Bullet blender tissue homogeniser (Gold units, Next Advance, USA). The mTOR signaling 
pathway exerts its effects via the phosphorylation of downstream targets such as ribosomal S6 kinase (S6K1). 
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To assess mTOR activity membranes were probed, as per the Western blotting experiments above, for phospho-
S6K1 (Thr-389, #9234, 84.2 ng/ml) and S6K1 (#2708, 48.0 ng/ml, both Cell Signaling Technologies, USA). All 
blots were re-probed with β-actin as a loading control (Sigma-Aldrich, UK, A5441, 1 µg/ml).
extraction of total RnA from human placental villous tissue. Total RNA was isolated from AGA 
(n = 11) and FGR (n = 9) villous tissue samples using the mirVanaTM isolation kit (AM1560, Ambion, LifeTech-
nologies, UK) following the manufacturer’s protocol. Samples were treated with DNAse using TURBO DNA-
freeTM kit (AM1906, Ambion, LifeTechnologies, UK) following the manufacturer’s instructions. RNA purity 
and concentration were assessed (Nanodrop 2000c, ThermoFisher Scientific, UK; 260/280 ratio of 2.0 ± 0.2 
was considered acceptable). Samples were stored at − 80 °C. cDNA was synthesised from 500 ng RNA using an 
AffinityScript Multiple Temperature cDNA Synthesis Kit (Agilent Technologies, Stratagene, UK). A reference 
total human placental RNA (1 μg, AM7950, Ambion, Life Technologies, UK) and negative controls (no reverse 
transcriptase: − RT and no RNA template control: NTC) were also included. 3 μl random primers (0.1 μg/μl) 
was added to each tube, incubated at 65 °C for 5 min and subsequently cooled at room temperature for 10 min 
to allow primers to anneal to the RNA. 2 μl 10 × AffinityScript RT Buffer, 0.8 μl dNTP mix (25 mM of each 
dNTP), 0.5 μl RNase Block Ribonuclease Inhibitor (40 U/μl) and 1 μl AffinityScript Multiple Temperature RT 
were added to give a final volume of 20 μl. The reaction was incubated at 25 °C for 10 min to extend the primers, 
42 °C for 60 min to generate cDNA, then terminated by incubation at 70 °C for 15 min. A pooled cDNA sample 
was generated by collecting 5 μl of each undiluted cDNA sample. The cDNA pool was diluted 1:4 in PCR  H2O 
then serially diluted to generate samples for a standard curve (1:4–1:256). All samples were stored at − 20 °C. The 
efficiency of reverse transcription was checked against a housekeeping gene (TATA-box binding protein, TBP).
Quantitative real‑time PCR (qRT‑PCR) of mRNA. A mastermix for qRT-PCR was prepared per reac-
tion as follows: 0.2 μl PCR  H2O, 5 μl 2X SYBR Green QPCR master mix, 0.3 μl ROX (reference dye, diluted 1:500 in 
PCR  H2O) (Brilliant III Ultra-fast SYBR Green Master Mix, Agilent Technologies, Wokingham, UK) and 0.25 μl 
of each forward and reverse primer (final concentration 300 nM) for the gene of interest. Primer sequences were 
as follows: SLC38A1 (5′-GTG TAT GCT TTA CCC ACC ATTGC-3′ and 3′-GCA CGT TGT CAT AGA ATG TCA 
AGT -5′), SLC38A2 (5′-ACG AAA CAA TAA ACA CCA CCT TAA -3′ and 3′-AGA TCA GAA TTG GCA CAG CATA-
5′), SLC38A4 (5′-TTG CCG CCC TCT TTG GTT AC-3′ and 3′-GAG GAC AAT GGG CAC AGT TAGT-5′), and TBP 
(5′-CAC GAA CCA CGG CAC TGA TT-3′ and 3′-TTT TCT TGC TGC CAG TCT GGAC-5′) used  previously45,53. 
Tyrosine 3- monooxygenase/tryptophan 5-monooxygenase activation protein zeta (YWHAZ) primers (5′-CCT 
GCA TGA AGT CTG TAA CTGAG-3′ and 3′-TTG AGA CGA CCC TCC AAG ATG-5′). 4 μl cDNA samples (diluted 
1:10 in PCR  H2O, 10 ng cDNA) were mixed with 6 μl master mix and measured in duplicate. A standard curve 
and negative controls (–RT, NTC) were included in duplicate on each plate. Conditions for qPCR (Stratagene 
MX3005P) were as follows: 95 °C 5 min, then 95 °C 30 s, 60 °C 30 s, 72 °C 30 s (40 cycles, amplification), 95 °C 
1 min, 55 °C 30 s then a final increase to 95 °C (in 0.2 °C increments) to generate a dissociation curve; a single 
peak and an efficiency between 90 and 110% was considered acceptable. Cycle threshold (CT) values were inter-
polated from the standard curve on each plate, generated from the pooled cDNA sample to calculate mRNA 
levels. mRNA expression was normalised to the geometric mean of TBP and YWHAZ (stable across samples, 
data not shown).
Statistical analysis. Data were analysed using GraphPad Prism 7 software; P < 0.05 was considered statisti-
cally significant. Normal distribution was determined using D’Agostino & Pearson omnibus normality test. Data 
from amino acid experiments are expressed as mean ± standard error of the mean (SEM), and least squares lin-
ear regression analyses performed to determine whether transporter-mediated amino acid uptake was linearly 
related to time and whether there were differences in amino acid uptake in AGA versus FGR. Western blot data 
were analysed using a Mann–Whitney test (transporter proteins) or 2-way repeated measures ANOVA with 
Sidak test (phospho-S6K1 and total S6K1). mRNA expression was analysed using a Mann–Whitney test. The 
effect of rapamycin on amino acid uptake was assessed by ANOVA with Dunn’s multi-comparison post hoc test 
with values represented as median. Wilcoxon matched pairs and Mann–Whitney tests were used to assess the 
effect of ouabain or unlabelled amino acids on uptake, respectively.
ethical approval and informed consent. This study was performed with local research ethics com-
mittee approval (15/NW/0829) and in accordance with relevant guidelines and regulations. Informed written 
consent from all participants was obtained during pregnancy prior to collection of samples.
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